What is claimed is:

1. A tablet for oral administration, which disintegrates in the oral cavity within 60 seconds, consisting essentially of (i) a therapeutically effective amount of an active ingredient, (ii) spray-dried mannitol, of which at least 80% has an average particle size over 100 μm, (iii) crospovidone, and (iv) one or more pharmaceutically acceptable excipients, the tablet containing no microcrystalline cellulose.

2. The tablet of claim 1, wherein the contents of the spray-dried mannitol and the crospovidone are in the ranges of 30 to 95% and 1 to 10% by weight, respectively, based on total weight of the tablet.

3. The tablet of claim 1, wherein the active ingredient is selected from the group consisting of acetaminophen, domperidone, famotidine, meclizine hydrochloride, scopolamine hydrobromide, ondansetron hydrochloride, cisapride, granisetron, sildenafil, loratadine and amlodipine.

4. A process for the preparation of a tablet according to claim 1, comprising direct-compressing a mixture consisting essentially of (i) a therapeutically effective amount of an active ingredient, (ii) spray-dried mannitol, of which at least 80% has an average particle size over 100 μm, (iii) crospovidone, and (iv) one or more pharmaceutically acceptable excipients, the tablet containing no microcrystalline cellulose.